After attending the sarcoma session of the 1990 meeting of the American Society for Clinical Oncology, one might be forgiven for wondering if chemotherapy for metastatic soft tissue sarcoma (STS) has come a full circle. It is 18 years since the South West Oncology Group (SWOG) published results of the first large scale study of doxorubicin (ADR) (O 'Bryan et al., 1973) . In 45 evaluable patients there were 13 complete and partial responses, giving an overall response rate of 29%. Since that time a variety of combination chemotherapy regimens have been tested, with overall response rates as high as 71% (Bodey et al., 1981) . Yet, in the largest randomised phase III trial ever performed in metastatic STS (Santoro et al., 1990 ) the European Organisation for Research and Treatment of Cancer (EORTC) has failed to demonstrate superiority for combination chemotherapy, based on cyclophosphamide or ifosfamide, compared with doxorubicin alone. Why should this be, and does it mean we have reached an impasse in the management of this disease, once it is disseminated?
SWOG explored the addition of other agents to doxorubicin in a logical sequence of studies (Gottlieb et al., 1975) , but individual regimens were not compared with each other in randomised trials. The rationale for adding dacarbazine (DIC) was its proven, although limited activity as a single agent . However, the addition of cyclophosphamide (CYCLO) and vincristine (VCR) was purely speculative based on the efficacy of these drugs in childhood sarcomas. This series of studies (Gottlieb et al., 1975) showed respective response rates of 31%, 42%, 42% and 55% for ADR alone, ADIC, VADIC and CYVADIC (CYCLO + VCR + ADR + DIC). Exclusion of bone tumours from the CYVADIC study left a total of 118 patients with STS, in whom the response rate was 59%. Since then, despite marginal activity as single agents, other drugs such as actinomycin D Schoenfeld et al., 1982) , cisplatinum (Edmonson et al., 1983 (Edmonson et al., , 1985 Cormier et al., 1986) and methotrexate (Bryant et al., 1980; Lynch et al., 1982; Presgrave et al., 1987) have been incorporated into ADR based combinations. Although there were insignificant differences in response rate and survival when actinomycin D (DACT) was substituted for DIC in CYVADIC in a subsequent randomised trial of SWOG, other combinations including DACT had limited activity (Schoenfeld et al., 1982) . Thus, in the late 1970's CYVADIC became a standard treatment, and was the subject of at least ten large scale studies (Bramwell, 1988 (Giuliano et al., 1978) through 27% (Karakousis et al., 1982) and 39% (Pinedo et al., 1985) to 48% (Bui et al., 1985) . In 1980, Yap et al. reanalysed the SWOG data set from the first CYVADIC study with STS deemed to be eligible, the overall response rate was somewhat lower at 50%. Many investigators started to question the contribution of CYCLO and VCR, and there was a move back to ADR/DIC combinations, which permitted the use of a slightly higher dose of ADR (60 mg m-2 vs 50 mg m-2 in CYVADIC). Surprisingly ADIC has never been compared directly with CYVADIC in a large scale randomised trial.
ECOG carried out one of the earliest randomised studies evaluating the efficacy of high dose ADR (70 mg m-2 every 3 weeks), in comparison with two combination chemotherapy regimens (Schoenfeld et al., 1982) . ADR was statistically superior to VAC (VCR + DACT + CYCLO) with respective response rates of 27% and 11%, confirming the lack of efficacy of DACT containing combinations in adult STS. Although the response rate for single agent ADR was higher than the 19% achieved with the second combination regimen (VCR + ADR + CYCLO) used in this study, the difference was not significant. A later trial by SWOG, randomising 335 patients (Baker et al., 1987) , showed that adding CYCLO or DACT to the ADIC regimen did not significantly improve response rates, which were respectively 33% (ADIC), 34% (CYCLO/ADIC) and 24% (DACT/ADIC).
ECOG performed another three arm trial (Bordon et al., 1987) in which patients were randomised to high dose ADR as described above (Schoenfeld et al., 1982) ; or to ADR 20mg m2 dl,2,3 followed by 15 mg m-2 d8 and weekly thereafter; or to ADIC. The response rate to ADIC was significantly better at 30% (P<0.02), compared with 18% and 16% for the 3 weekly and loading/weekly dose schedules of ADR, although complete response rates, durations of response and survival were similar for the three regimens. The authors' conclusion questioning 'whether the increased response frequency, without an impact on survival, is worth the significantly greater toxicity' was criticised in an accompanying editorial (Benjamin, 1987) , which suggested that higher doses of ADIC incorporating Ifosfamide (IFOS) initially or subsequently should be pursued. Another interesting point, not commented on in the paper or editorial is that the response rate in this second ECOG study, to the 3 weekly schedule of ADR was low compared with the previous study, 18% vs 27%, although the dose/schedule was identical. Because of variability in patient populations, direct comparisons between studies have limited value. However, a response rate of 27% is in keeping with many other studies of intermittent high dose ADR (Bramwell et al., 1983; Mouridsen et al., 1987; Santoro et al., 1990) , and is similar to the respose rate for ADIC (30%) in this second ECOG trial (Bordon et al., 1987) and for ADIC (33%) in the SWOG trial (Baker et al., 1987 ). Benjamin's editorial (1987) suggested that 'IFOS intensification' might produce better results. IFOS had been synthesised in Germany in the 1960's, and shown to have a broad spectrum of activity, but a high incidence of haemorrhagic cystitis had discouraged its widespread use. The discovery of Mesna, a sulphydryl donor, which neutralises the toxic byproduct acrolein in the bladder, led to a re-evaluation of IFOS in the 1980's, and promising results were reported 8 V.H.C. BRAMWELL for STS (Stuart-Harris et al., 1983; Bramwell et al., 1986; Antman et al., 1989) . Preliminary data suggested that response rates between 25-35% could be achieved in patients not previously exposed to chemotherapy. Such activity was higher than that seen for any single agent other than ADR. A randomised study (Bramwell et al., 1986) conducted by the EORTC demonstrated that IFOS 5 g m-2 q 3 weeks was more active than CYCLO 1.5 g m-2, but less myelosuppressive and could be incorporated without dose reduction into combination chemotherapy with 50-60 mg m2 ADR.
US investigators chose to incorporate IFOS into the ADIC combination, and early results for a high dose 96 h infusional regimen, MAID, were extremely promising It is tempting to conclude from these data that single agent ADR in doses of > 70 mg m-2 q 3 weeks should be the standard treatment for patients wishing to receive palliative chemotherapy outside a clinical trial. Prolonged infusions, splitting the dose over several days, or weekly treatment, may reduce toxicity but add to the inconvenience.
A corollary of this conclusion would be the recommendation that promising new treatments should be compared, at the earliest opportunity, with high dose single agent ADR in a randomised phase III setting.
In the research setting, should we continue to explore other avenues, or are these results so depressing that we should abandon the intense investigation of these rare tumours? I remain optimistic that progress can be made. Strategies should include:
(a) identification of new active agents, preferably with novel structures and different modes of action and toxicity; (b) synthesis of analogues of current effective agents, especially if the structural changes might enhance activity; (c) definition of improved/dose schedules which might optimise activity particularly for new agents such as IFOS;
(d) dose intensification which may be permitted by growth factor support and (e) novel approaches, exploiting discoveries in the rapidly expanding field of molecular biology which improve our understanding of patterns of failure and mechanisms of drug resistance. Studies are currently underway in most of these areas. Drugs with novel structures should be tested in STS, although the smaller potential market may not make this a top priority for industry sponsored trials. Analogues of anthracyclines and alkylating agents are obvious candidates for testing in STS, but anti-folates are an additional interesting group. Early reports (Subramanian & Wiltshaw, 1978) of significant activity for MTX have not been substantiated (Presgrave et al., 1987; Pfeffer et al., 1988) , but the Canadian Sarcoma Group (CSG) has reported that trimetrexate has modest activity in previously untreated patients (Quirt et al., 1988) . Unfortunately, it seems unlikely that this drug will be developed as an anticancer agent because of its limited activity in other tumour types and unpredictable myelotoxicity. Another promising anti-folate, 10-EDAM, is currently being studied by the CSG. The limited efficacy of current single agent and combination chemotherapy in STS, makes it entirely feasible to propose single agent investigational drug therapy to patients as first line therapy, with the option to proceed to standard ADR, alone or in combination, if this fails. German groups (Hilgard et al., 1983; Brade et al., 1985) have led the field in exploring high and prolonged dose/ schedules of IFOS, but comnparative studies are lacking.
Strategy (d) has been pursued by the EORTC, which has used GM-CSF to permit dose intensification of ADR + IFOS, escalating ADR to 75 mg m2. Early results (unpublished) are promising, and a randomised trial comparing this dose escalated regimen with standard dose ADR + IFOS will soon be initiated. This approach has similarities to that reported by Bodey et al. in 1981 , who administered escalated doses of CYVADIC in the setting of a protected environment-prophylactic antibiotic program. In a small group of patients, a higher response rate (71%) was achieved and, despite profound myelosuppression, infective episodes were no more frequent than with standard therapy. Although it achieved its objectives, the inconvenience and costs of such a program in a palliative setting have limited its use. It remains to be seen whether GM-CSF regimens will prove to be of benefit, and cost-effective in this setting.
There have been many interesting findings relevant to STS in the field of molecular biology. Specific chromosomal breaks have been associated with particular subtypes of sarcomas , over expression of the MDR-1 gene may be linked with resistance to certain chemotherapeutic drugs (Gerlach et al., 1987; Chan et al., 1990) and other mechanisms of resistance are being explored. Different levels of oncogene expression may have a bearing on the behaviour of STS (Fahrer et al., 1989; Kato et al., 1990) and further elucidation of these patterns might gives us clues to alternative treatment strategies.
In conclusion, identification of substantially more active drugs or combination chemotherapy will provide not only a better means of palliating metastatic disease, but might also have the potential to cure patients if used appropriately as adjuvant treatment.
